HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rapp, J. H. Articles by Weisskoff, R. M. Search for Related Content PubMed PubMed Citation Articles by Rapp, J. H. Articles by Weisskoff, R. M.

Aortoiliac Occlusive Disease in Patients with Known or Suspected Peripheral Vascular Disease: Safety and Efficacy of Gadofosveset-enhanced MR Angiography—Multicenter Comparative Phase III Study¹

¹ From the Surgical Service (112G), San Francisco DVA Medical Center, 4150 Clement St, San Francisco, CA 94121 (J.H.R.). The complete list of author affiliations appears at the end of this article. Received January 26, 2004; revision requested April 6; revision received August 6; accepted September 8. Address correspondence to J.H.R. (e-mail: rappj{at}surgery.ucsf.edu).

PURPOSE: To prospectively determine the safety and efficacy of the gadolinium-based blood pool magnetic resonance (MR) imaging contrast agent gadofosveset in patients known to have or suspected of having peripheral vascular disease.

MATERIALS AND METHODS: Ethical committee approval and patient written informed consent were obtained. This study was compliant with the Health Insurance Portability and Accountability Act. Adults known or suspected to have peripheral vascular disease received gadofosveset (0.03 mmol per kilogram of body weight) for MR angiography of the aortoiliac region. Gadofosveset-enhanced MR angiography and unenhanced two-dimensional time-of-flight MR angiography were compared with the reference standard, conventional angiography, for the presence of vascular stenosis. All patients were monitored for adverse events with hematologic analysis, analysis of blood chemistry, urinalysis, and electrocardiographic parameters; these methods were analyzed to determine safety.

RESULTS: A total of 274 patients were enrolled at 37 centers. Gadofosveset-enhanced MR angiography showed significant improvement (P < .001) compared with unenhanced MR angiography for each of the readers for diagnosis of clinically significant (50%) stenosis. Specificity and accuracy were significantly greater for three readers, and sensitivity increased significantly for two readers. For all readers, the area under the receiver operator characteristic curve for both quantitative and qualitative measures of significant disease increased (P < .001) for gadofosveset-enhanced MR angiography versus two-dimensional time-of-flight MR angiography. All readers also expressed more confidence in diagnosis (P < .001) and found fewer images to be uninterpretable (0.5% vs 11.0%). The most common adverse events were as follows: feeling hot, 12 (4.4%) patients; nausea, 10 (3.6%) patients; headache, nine (3.3%) patients; and burning sensation, eight (2.9%) patients. Only four serious adverse events were reported, in three patients, and all events were rated as unlikely related to the drug. No patients were excluded because of adverse events or laboratory abnormalities. There were no clinically important trends in the findings of hematologic analysis, blood chemistry, urinalysis, electrocardiography, or physical examination.

CONCLUSION: On the basis of substantial improvements over noncontrast MR angiography in efficacy and a minimal and transient side-effect profile, gadofosveset was found to be safe and effective for MR angiography in patients known or suspected to have peripheral vascular disease.

© RSNA, 2005

This article has been cited by other articles:

				D. R. Hadizadeh, J. Gieseke, S. H. Lohmaier, K. Wilhelm, J. Boschewitz, F. Verrel, H. H. Schild, and W. A. Willinek Peripheral MR Angiography with Blood Pool Contrast Agent: Prospective Intraindividual Comparative Study of High-Spatial-Resolution Steady-State MR Angiography versus Standard-Resolution First-Pass MR Angiography and DSA Radiology, September 3, 2008; (2008) 2492072033. [Abstract] [Full Text]

				H. Ersoy and F. J. Rybicki MR Angiography of the Lower Extremities Am. J. Roentgenol., June 1, 2008; 190(6): 1675 - 1684. [Abstract] [Full Text] [PDF]

				G. Soulez, M. Pasowicz, G. Benea, L. Grazioli, J. P. Niedmann, M. Konopka, P. C. Douek, G. Morana, F. K. W. Schaefer, A. Vanzulli, et al. Renal Artery Stenosis Evaluation: Diagnostic Performance of Gadobenate Dimeglumine-enhanced MR Angiography--Comparison with DSA Radiology, April 1, 2008; 247(1): 273 - 285. [Abstract] [Full Text] [PDF]

				E. Bosch, K.-F. Kreitner, M. F. Peirano, S. Thurner, K. Shamsi, and E. C. Parsons Jr. Safety and Efficacy of Gadofosveset-Enhanced MR Angiography for Evaluation of Pedal Arterial Disease: Multicenter Comparative Phase 3 Study Am. J. Roentgenol., January 1, 2008; 190(1): 179 - 186. [Abstract] [Full Text] [PDF]

				S. Thurnher, S. Miller, G. Schneider, C. Ballarati, G. Bongartz, C. U. Herborn, S. Schoenberg, M. A. Cova, G. Morana, K. Niazi, et al. Diagnostic Performance of Gadobenate Dimeglumine Enhanced MR Angiography of the Iliofemoral and Calf Arteries: A Large-Scale Multicenter Trial Am. J. Roentgenol., November 1, 2007; 189(5): 1223 - 1237. [Abstract] [Full Text] [PDF]

				K. Nikolaou, H. Kramer, C. Grosse, D. Clevert, O. Dietrich, M. Hartmann, P. Chamberlin, S. Assmann, M. F. Reiser, and S. O. Schoenberg High-Spatial-Resolution Multistation MR Angiography with Parallel Imaging and Blood Pool Contrast Agent: Initial Experience Radiology, December 1, 2006; 241(3): 861 - 872. [Abstract] [Full Text] [PDF]